Patents Assigned to LUDWIG INSTITUT FOR CANCER RESEARCH
  • Recombinant adenylate cyclase toxin of induces T cell responses against tumoral antigens
    Patent number: 9410139
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 9, 2016
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), LUDWIG INSTITUT FOR CANCER RESEARCH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoît Van Den Eynde, Sandra Morel, Cécile Bauche